Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sernova Corp T.SVA

Alternate Symbol(s):  SEOVF

Sernova Corp. is a Canada-based clinical-stage biotechnology company, which is developing therapeutic cell technologies for chronic diseases, including insulin-dependent diabetes, thyroid disease, and blood disorders that include hemophilia A. The Company is focused on developing a functional cure for insulin-dependent diabetes with its therapeutic cell technology, the Cell Pouch System, a novel implantable and scalable medical device with immune protected therapeutic cells. The Cell Pouch is a scalable, implantable medical device. The Cell Pouch is designed to create a vascularized organ-like environment for the transplantation and engraftment of therapeutic cells. Its regenerative medicine therapeutic approach is to provide cell therapies where the cells, transplanted within an organ-like vascularized implantable device, the Cell Pouch, generates proteins, hormones or factors released into the bloodstream for treatment of diseases requiring replacement of these molecules in the body.


TSX:SVA - Post by User

Comment by steadfaston Apr 04, 2021 2:09pm
151 Views
Post# 32935212

RE:Scientific success vs. commercialization

RE:Scientific success vs. commercializationSailboatdream:
The answer to your ? is very clear.  Why peer valuation not achieved.  We had one or maybe two
chances, both hurt  by timing of Mgt and Board of Directors arranging  financing deals immediately following Dr. Witkoski presenting:
July 3 2019     Dr W presents Lyon France - good results
July 4, 2019    Rumour PP coming, - true
Stock did not get a chance to see what it could do.  Momentum was not there like
it was in 2021, consequently there may not have been an opportuntiy to achieve much.
Jan 14, 2021  Sva close 75 cents - momentum building
Jan 15, 2021  Sva close $1.24      - momentum very strong
Jan 18, 2021  Sva hits $2.87 shortly after open, Dr Loe, Leede  puts out his $2.50 report,
                    stock sells down.  sva may  have achieved $3.95 by wk end,which it needs today
                    with 317M fully diluted shares o/s - $1.25 B Can = $1B U.S.
Jan 28, 2021  SVA closes 1.47  another financing bot deal.  All short term hope gone.
June 28, 2021 We may have a 3rd Chance with Dr W presenting

God help anyone getting in our way this time.
What is done is done, we have $23M in bank from bot deal.
We need some good Analyst Reports with a decent target, not $2.50 we need
$3.95 minimum to be on par with peers.  Suspect our science is worth more than Semma & Sigilon. They have deep pockets.  We are a small Canadian Company.





<< Previous
Bullboard Posts
Next >>